Clovis Oncology (CLVS) to Release Earnings on Thursday

Clovis Oncology (NASDAQ:CLVS) will release its earnings data before the market opens on Thursday, August 1st. Analysts expect Clovis Oncology to post earnings of ($1.70) per share for the quarter.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.17. Clovis Oncology had a negative return on equity of 196.39% and a negative net margin of 342.54%. The firm had revenue of $33.12 million for the quarter, compared to analysts’ expectations of $32.10 million. During the same quarter last year, the business earned ($1.38) earnings per share. The company’s revenue was up 78.8% compared to the same quarter last year. On average, analysts expect Clovis Oncology to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of CLVS opened at $10.70 on Tuesday. The company has a debt-to-equity ratio of 8.04, a quick ratio of 4.15 and a current ratio of 4.39. Clovis Oncology has a 1 year low of $10.42 and a 1 year high of $46.79. The company has a market capitalization of $571.92 million, a PE ratio of -1.51 and a beta of 1.92. The stock’s 50-day moving average is $13.19.

In other news, insider Lindsey Rolfe sold 1,728 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $14.70, for a total transaction of $25,401.60. Following the sale, the insider now owns 23,319 shares of the company’s stock, valued at $342,789.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 2,452 shares of company stock worth $36,261. 8.30% of the stock is currently owned by insiders.

A number of brokerages have issued reports on CLVS. Goldman Sachs Group upgraded Koninklijke KPN from a “neutral” rating to a “buy” rating in a report on Wednesday, May 29th. JPMorgan Chase & Co. upgraded ROYAL MAIL PLC/ADR from an “underweight” rating to a “neutral” rating in a report on Monday, June 3rd. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. BidaskClub cut Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, SunTrust Banks raised their target price on Edison International to $77.00 and gave the stock a “positive” rating in a report on Monday, April 15th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the stock. Clovis Oncology presently has an average rating of “Hold” and a consensus price target of $27.44.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Read More: Cryptocurrencies

Receive News & Ratings for Clovis Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Clovis Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.